Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Akorn, Inc. (NASDAQ: AKRX) today announced that the U.S. Federal Trade Commission (FTC) has voted to approve Akorn’s acquisition of Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK). The unanimous vote in support of the transactions follows Akorn’s ...
read more
Wednesday, August 08, 2012
Akorn, Inc. (NASDAQ: AKRX), a niche generic pharmaceutical company, today announced the appointment of Bruce Kutinsky as its Chief Operating Officer of its US operations effective September 1, 2012. Mr. Kutinsky was most recently the President of ...
read more
Akers Biosciences announced Premas Biotech, its partner in the development of a vaccine candidate that is seeking to address the COVID-19 pandemic, has successfully completed its vaccine prototype.
read more
Wednesday, March 06, 2013
Ajinomoto Co., Inc. (“Ajinomoto Co.”; TYO: 2802) and Althea Technologies, Inc. (“Althea Technologies”), announced today that they have entered into a definitive agreement by which Ajinomoto Co. will acquire Althea Technologies, a leading provider of ...
read more
Monday, December 28, 2020
Ajinomoto Bio-Pharma Services and Revance Therapeutics have announced a commercial manufacturing agreement for the supply of DaxibotulinumtoxinA for Injection.
read more
Thursday, October 01, 2020
Ajinomoto Bio-Pharma has announce a supply partnership with the DNDi for the supply of a CpG oligonucleotide, as part of a combination therapy used in the treatment of cutaneous leishmaniasis infections.
read more
Ajinomoto Bio-Pharma Services has entered into a manufacturing agreement with Humanigen for the fill finish supply of lenzilumab currently being studied in a trial for COVID-19.
read more
Thursday, August 13, 2020
Ajinomoto Bio-Pharma has announced an expansion of small molecule manufacturing capabilities with the addition of a new production facility in India.
read more
Tuesday, January 25, 2022
Ajinomoto Bio-Pharma Services announced that Tony O'Neill has joined Aji Bio-Pharma as Vice President of Compliance, US Operations. Mr. O'Neill brings extensive experience leading Quality, Manufacturing, and Operational Excellence Teams in the ...
read more
Ajinomoto Bio-Pharma Services (Aji Bio-Pharma), a leading provider of biopharmaceutical contract development and manufacturing services, announced the opening of a high-speed multi-purpose fill finish line in its state-of-the-art commercial ...
read more
Ajinomoto Bio-Pharma Services has announced the launch of AJILITY™, a flexible and agile drug product manufacturing platform.
read more
Ajinomoto Bio-Pharma Services has completed the acquisition of Granules OmniChem Private, purchasing the remaining 50 percent ownership interest from Granules India.
read more
Thursday, December 10, 2015
Ajinomoto Althea, Inc. (“Althea”) recently announced it is expanding its existing biological drug product manufacturing operations to include highly active materials such as Antibody Drug Conjugates (ADCs).
read more
Ajinomoto Althea, Inc. announced today it is expanding the capacity of its Fill and Finish operations through the addition of a second manufacturing shift.
read more
Wednesday, October 14, 2015
Ajinomoto Althea, Inc. today announced it is expanding its existing biological drug product manufacturing operations to include highly active materials such as Antibody Drug Conjugates (ADCs). The new facility is located in close proximity to ...
read more